Physician profile
Hemangini Shah
NPI 1336162015
$3,110.57
in general payments reported to CMS, 2019-2025
35 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $551 · 2021: $591 · 2022: $168 · 2023: $297 · 2024: $507 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $370.45 | 2020-2021 | |
| Bioprotect Medical, INC. | $314.11 | 2025 | Bioprotect Balloon Implant System |
| Janssen Biotech, INC. | $228.11 | 2020-2022 | |
| Abbott Laboratories | $160.01 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $152.63 | 2020-2023 | Imfinzi |
| Coherus Oncology, INC. | $138.30 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $132.18 | 2019-2024 | Libtayo |
| Silk Road Medical, INC. | $122.03 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Becton, Dickinson and Company | $120.81 | 2024 | Phasix Mesh |
| Pharmacyclics LLC, An Abbvie Company | $116.50 | 2022 | |
| Verastem, INC. | $114.19 | 2019 | |
| Heron Therapeutics, INC. | $114.19 | 2019 | |
| Abbvie INC. | $109.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.00 | 2021 | |
| Beigene USA, INC. | $97.66 | 2024 | Brukinsa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zap Surgical Systems, INC. | $95.69 | 2024 | Zap-X Treatment Planning Software, Zap-X Treatment Delivery Software, Zap-X Radiosurgery System |
| Seagen INC. | $78.37 | 2020-2023 | |
| Incyte Corporation | $57.92 | 2020-2021 | |
| Celgene Corporation | $51.98 | 2019-2020 | |
| Pfizer INC. | $50.35 | 2020-2025 | |
| Genzyme Corporation | $48.39 | 2019-2021 | |
| Exelixis INC. | $44.21 | 2020 | |
| Blue Earth Diagnostics | $37.32 | 2024 | |
| Telix Pharmaceuticals | $36.44 | 2025 | Illuccix |
| Boston Scientific Corporation | $31.37 | 2025 | Spaceoar Vue System - 10ml |
| Eisai INC. | $27.99 | 2021 | |
| Teleflex LLC | $26.65 | 2024 | |
| Lilly USA, LLC | $24.18 | 2020 | |
| Progenics Pharmaceuticals, INC. | $23.74 | 2025 | |
| Novocure INC. | $21.66 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.20 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.26 | 2019 | |
| Astellas Pharma US INC | $11.49 | 2020 | |
| Eusa Pharma (US) LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemangini Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.